PT  - JOURNAL ARTICLE
AU  - Kei Miyakawa
AU  - Sundararaj Stanleyraj Jeremiah
AU  - Hideaki Kato
AU  - Akihide Ryo
TI  - Neutralizing efficacy of vaccines against the SARS-CoV-2 Mu variant
AID  - 10.1101/2021.09.23.21264014
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.23.21264014
4099  - http://medrxiv.org/content/early/2021/09/26/2021.09.23.21264014.short
4100  - http://medrxiv.org/content/early/2021/09/26/2021.09.23.21264014.full
AB  - The rise of mutant strains of SARS-CoV-2 poses an additional problem to the existing pandemic of COVID-19. There are rising concerns about the Mu variant which can escape humoral immunity acquired from infections from previous strains or vaccines. We examined the neutralizing efficacy of the BNT162b2 mRNA vaccine against the Mu variant and report that the vaccine has 76% neutralizing effectiveness against the Mu compared to 96% with the original strain. We also show that Mu, similar to the Delta variant, causes cell-to-cell fusion which can be an additional factor for the variant to escape vaccine-mediated humoral immunity. Despite the rise in vaccine escape strains, the vaccine still possesses adequate ability to neutralize majority of the mutants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by AMED grants (JP20he0522001, JP21fk0108104).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Yokohama City University Certified Institutional Review Board (Reference No. B210300001), and the protocols used in the study were approved by the ethics committee. Written informed consent was obtained from all the participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets presented in this article are not readily available because it is difficult to ensure the de-identification of data. However, they can be available from the corresponding authors on reasonable request.